Skye Bioscience (SKYE) Operating Expenses (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Operating Expenses of $12.7 million for Q1 2026, up 7.78% year-over-year from $11.8 million in Q1 2025, and down 14.91% quarter-over-quarter from $14.9 million in Q4 2025.
Skye Bioscience (SKYE) Operating Expenses (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Operating Expenses for 15 consecutive years, with $12.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 7.78% year-over-year to $12.7 million; the TTM figure through Mar 2026 stood at $59.1 million (up 65.02% YoY), while the FY2025 annual figure was $58.2 million, up 92.64% from the prior year.
- Operating Expenses declined to $12.7 million in Q1 2026 per SKYE's latest filing, from $14.9 million in the prior quarter.
- Across five years, Operating Expenses topped out at $24.7 million in Q3 2023 and bottomed at $2.8 million in Q2 2023.
- Historically, Operating Expenses has averaged $9.1 million across 5 years, with a median of $8.4 million in 2024.
- Annual changes were most pronounced in 2023 — Operating Expenses surged 745.43% — and 2024, when it slumped 79.89%.
- Skye Bioscience's Operating Expenses stood at $9.3 million in 2022, then plunged by 55.98% to $4.1 million in 2023, then surged by 161.02% to $10.7 million in 2024, then surged by 39.65% to $14.9 million in 2025, then retreated by 14.91% to $12.7 million in 2026.
- Business Quant data shows SKYE's Operating Expenses at $12.7 million in Q1 2026, $14.9 million in Q4 2025, and $13.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Skye Bioscience | 11.17 Mn | 11.17 Mn | - | 11.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.67 Mn |
| Dec 31, 2025 | 14.90 Mn |
| Sep 30, 2025 | 13.26 Mn |
| Jun 30, 2025 | 18.24 Mn |
| Mar 31, 2025 | 11.76 Mn |
| Dec 31, 2024 | 10.67 Mn |
| Sep 30, 2024 | 4.97 Mn |
| Jun 30, 2024 | 8.41 Mn |
| Mar 31, 2024 | 6.15 Mn |
| Dec 31, 2023 | 4.09 Mn |
| Sep 30, 2023 | 24.71 Mn |
| Jun 30, 2023 | 2.84 Mn |
| Mar 31, 2023 | 3.10 Mn |
| Dec 31, 2022 | 9.28 Mn |
| Sep 30, 2022 | 2.92 Mn |
| Jun 30, 2022 | 3.22 Mn |
| Mar 31, 2022 | 2.89 Mn |
| Dec 31, 2021 | 2.46 Mn |
| Sep 30, 2021 | 1.82 Mn |
| Jun 30, 2021 | 1.83 Mn |